New molecular entities/new biologics - Boniva - Ibandronate - Roche/Glaxosmithkline - Treatment and prevention of osteoporosis

被引：0

|

作者：

不详

机构：

来源：

FORMULARY | 2003年 / 38卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：392 / 392

页数：1

相关论文

共 50 条

[1] Boniva - Ibandronate 150-mg tablets - Roche/GlaxoSmithKline - First once-monthly therapy approved for treatment and prevention of osteoporosis
不详
FORMULARY, 2005, 40 (05) : 144 - 145
[2] Ibandronate (Boniva) Offers New Options for Osteoporosis
Kessenich, Cathy R.
NURSE PRACTITIONER, 2006, 31 (10): : 64 - 66
[3] Ibandronate (Boniva) for treatment and prevention of osteoporosis in postmenopausal women
Ference, JD
Wilson, SA
AMERICAN FAMILY PHYSICIAN, 2006, 73 (02) : 305 - 306
[4] New molecular entities/new biologics
不详
FORMULARY, 2003, 38 (12) : 670 - +
[5] New molecular entities/new biologics
不详
FORMULARY, 2003, 38 (01) : 7 - +
[6] New molecular entities/new biologics
不详
FORMULARY, 2003, 38 (05) : 256 - +
[7] New molecular entities/biologics
不详
FORMULARY, 2005, 40 (04) : 102 - 103
[8] New molecular entities/biologics
不详
FORMULARY, 2003, 38 (03) : 123 - 123
[9] Ibandronate: a new option in osteoporosis treatment
Sewerynek, Ewa
MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2006, 5 (04): : 231 - 238
[10] Ibandronate: New options in the treatment of osteoporosis
Adami, S
Viapiana, O
DRUGS OF TODAY, 2003, 39 (11) : 877 - 886

← 1 2 3 4 5 →